• 1
    Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 1321.
  • 2
    Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 40922.
  • 3
    Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 62832.
  • 4
    Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol 1985; 8: 7780.
  • 5
    Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997; 40: 293308.
  • 6
    Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977; 39: 135761.
  • 7
    Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 137281.
  • 8
    Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003; 52: 138.
  • 9
    Gandara DR, DeGregorio MW, Wold H, Wilbur BJ, Kohler M, Lawrence HJ, Deisseroth AB, George CB. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol 1986; 4: 178793.
  • 10
    Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 5749.
  • 11
    Kollmannsberger C, Kuzcyk M, Mayer F, Hartmann JT, Kanz L, Bokemeyer C. Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999; 17: 27581.
  • 12
    Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 8669.
  • 13
    Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Mockel C, Seeber S, Scheulen ME. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 22936.
  • 14
    Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 172532.
  • 15
    Smith E, Brock AP. The effect of reduced osmolarity on platinum drug toxicity. Br J Cancer 1989; 59: 8735.
  • 16
    Kondo A, Maeta M, Oka A, Tsujitani S, Ikeguchi M, Kaibara N. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 1996; 73: 116670.
  • 17
    Isambert N, Correia M, Cercueil JP, Zanetta S, Osmak L, Flesch M, Krause D, Coudert B, Fargeot P, Bedenne L, Chauffert B. Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study. J Exp Clin Cancer Res 2001; 20: 1838.
  • 18
    Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 1994; 45: 4857.
  • 19
    Delarue F, Virone A, Hagege J, Lacave R, Peraldi MN, Adida C, Rondeau E, Feunteun J, Sraer JD. Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. Kidney Int 1991; 40: 90612.
  • 20
    Caignard A, Pelletier H, Martin F. Specificity of the immune response leading to protection or enhancement by regressive and progressive variants of a rat colon carcinoma. Int J Cancer 1988; 42: 8836.
  • 21
    Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 1924.
  • 22
    Daley-Yates PT, McBrien DC. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985; 34: 23639.
  • 23
    Daley-Yates PT, McBrien DC. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid. Biochem Pharmacol 1982; 31: 22436.
  • 24
    Erlichman C, Soldin SJ, Thiessen JJ, Sturgeon JF, Fine S. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer. Cancer Chemother Pharmacol 1987; 19: 759.
  • 25
    Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 1990; 26: 27882.
  • 26
    Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 136271.
  • 27
    Jones TW, Chopra S, Kaufman JS, Flamenbaum W, Trump BF. Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab Invest 1985; 52: 36374.
  • 28
    Cai Q, Michea L, Andrews P, Zhang Z, Rocha G, Dmitrieva N, Burg MB. Rate of increase of osmolarity determines osmotic tolerance of mouse inner medullary epithelial cells. Am J Physiol Renal Physiol 2002; 283: 7928.
  • 29
    Gonzalez-Campoy JM, Knox FG. Integrated response of the kidney to alterations in extracellular fluid volume. In: SeldinDW, GiebischG. The kidney: physiology and pathophysiology, 2nd ed. New York: Raven Press, 1992. 204198.
  • 30
    Kim YK, Byun HS, Kim YH, Woo JS, Lee SH. Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol 1995; 130: 1926.
  • 31
    Safirstein R, Miller P, Dikman S, Lyman N, Shapiro C. Cisplatin nephrotoxicity in rats: defect in papillary hypertonicity. Am J Physiol 1981; 241: 17585.
  • 32
    Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 16972.
  • 33
    Kuhlmann MK, Burkhardt G, Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 1997; 12: 247880.
  • 34
    Kroning R, Katz D, Lichtenstein AK, Nagami GT. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines. Br J Cancer 1999; 79: 2939.
  • 35
    Lau AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 1999; 56: 12958.
  • 36
    Okuda M, Masaki K, Fukatsu S, Hashimoto Y, Inui K. Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. Biochem Pharmacol 2000; 59: 195201.
  • 37
    Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63: 7282.
  • 38
    Aamdal S, Fodstad O, Kaalhus O, Pihl A. Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle. J Natl Cancer Inst 1984; 73: 74352.
  • 39
    Castrop H, Vitzthum H, Schumacher K, Schweda F, Kurtz A. Low tonicity mediates a downregulation of cyclooxygenase-1 expression by furosemide in the rat renal papilla. J Am Soc Nephrol 2002; 13: 113644.